Advances in Treatment of Pediatric Brain Tumors

NeuroRx

Volumn 3, Issue 2, 2006, Pages 276-291

  Robertson, Patricia L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

chemotherapy; immunotherapy; neurosurgery; Pediatric brain tumor; radiation therapy; small molecule

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CILENGITIDE; CISPLATIN; CYCLOPAMINE; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; ERLOTINIB; EVEROLIMUS; GANCICLOVIR; GEFITINIB; IMATINIB; IRINOTECAN; LOMUSTINE; MONOCLONAL ANTIBODY; NITROSOUREA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISONE; PROCARBAZINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAPAMYCIN; RETINOID; TEMOZOLOMIDE; TIOGUANINE; TIPIFARNIB; TRANSFERRIN; TUMOR VACCINE; UNINDEXED DRUG; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; DRUG SAFETY; ELECTROPHYSIOLOGY; GENE REPLACEMENT THERAPY; GENE TARGETING; GLIOMA; HEALTH CARE QUALITY; HISTOPATHOLOGIC SKIN REACTION; HUMAN; MEDULLOBLASTOMA; MULTIMODALITY CANCER THERAPY; NEUROECTODERM TUMOR; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RADIATION DOSE; RETINOBLASTOMA; SAFETY; SIGNAL TRANSDUCTION; STEM CELL GENE THERAPY; STEREOTAXIC SURGERY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; VACCINATION; CHILD; NEUROLOGY; PEDIATRICS; REVIEW;

BRAIN NEOPLASMS; CHILD; HUMANS; NEUROLOGY; PEDIATRICS;

EID: 33646133206     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1016/j.nurx.2006.01.001     Document Type: Article

References (100)

1. Rosser T., and Packer R.J. Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol 17 8 (2002) 630-637 discussion 646-651
2. Robertson P.L., Allen J.C., Abbott I.R., Miller D.C., Fidel J., and Epstein F.J. Cervicomedullary tumors in children. a distinct subset of brainstem gliomas. Neurology 44 10 (1994) 1798-1803
3. Albright A.L., Packer R.J., Zimmerman R., Rorke L.B., Boyett J., and Hammond G.D. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas. a report from the Children's Cancer Group. Neurosurgery 33 6 (1993) 1026-1029 discussion 1029-1030
4. Law M. MR spectroscopy of brain tumors. Top Magn Reson Imaging 15 5 (2004) 291-313
5. Warren K.E., Frank J.A., Black J.L., Hill R.S., Duyn J.H., Aikin A.A., Lewis B.K., Adamson P.C., and Balis F.M. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 18 5 (2000) 1020-1026
6. Chenevert T.L., Meyer C.R., Moffat B.A., Rehemtulla A., Mukherji S.K., Gebarski S.S., Quint D.J., Robertson P.L., Lawrence T.S., Junck L., Taylor J.M., Johnson T.D., Dong Q., Muraszko K.M., Brunberg J.A., and Ross B.D. Diffusion MRI. a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 1 4 (2002) 336-343
7. Moffat B.A., Chenevert T.L., Lawrence T.S., Meyer C.R., Johnson T.D., Dong Q., Tsien C., Mukherji S., Quint D.J., Gebarski S.S., Robertson P.L., Junck L.R., Rehemtulla A., and Ross B.D. Functional diffusion map. a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102 15 (2005) 5524-5529
8. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., and Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133 4 (1984) 1710-1715
9. Pollack I.F., Hamilton R.L., Burnham J., Holmes E.J., Finkelstein S.D., Sposto R., Yates A.J., Boyett J.M., and Finlay J.L. Impact of proliferation index on outcome in childhood malignant gliomas. results in a multi-institutional cohort. Neurosurgery 50 6 (2002) 1238-1244 discussion 1244-1235
10. Fisher B.J., Naumova E., Leighton C.C., Naumov G.N., Kerklviet N., Fortin D., Macdonald D.R., Cairncross J.G., Bauman G.S., and Stitt L. Ki-67. a prognostic factor for low-grade glioma?. Int J Radiat Oncol Biol Phys 52 4 (2002) 996-1001
11. Grotzer M.A., Geoerger B., Janss A.J., Zhao H., Rorke L.B., and Phillips P.C. Prognostic significance of Ki-67 (MIB-1) proliferation index in childhood primitive neuroectodermal tumors of the central nervous system. Med Pediatr Oncol 36 2 (2001) 268-273
12. Pollack I.F., Finkelstein S.D., Burnham J., Holmes E.J., Hamilton R.L., Yates A.J., Finlay J.L., and Sposto R. Age and TP53 mutation frequency in childhood malignant gliomas. results in a multi-institutional cohort. Cancer Res 61 20 (2001) 7404-7407
13. Tremont-Lukats I.W., and Gilbert M.R. Advances in molecular therapies in patients with brain tumors. Cancer Control 10 2 (2003) 125-137
14. Pollack I.F., Finkelstein S.D., Woods J., Burnham J., Holmes E.J., Hamilton R.L., Yates A.J., Boyett J.M., Finlay J.L., and Sposto R. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346 6 (2002) 420-427
15. Sung T., Miller D.C., Hayes R.L., Alonso M., Yee H., and Newcomb E.W. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 10 2 (2000) 249-259
16. Segal R.A., Goumnerova L.C., Kwon Y.K., Stiles C.D., and Pomeroy S.L. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 91 26 (1994) 12867-12871
17. Scheurlen W.G., Schwabe G.C., Joos S., Mollenhauer J., Sorensen N., and Kuhl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16 7 (1998) 2478-2485
18. Packer R.J., Cogen P., Vezina G., and Rorke L.B. Medulloblastoma. clinical and biologic aspects. Neuro-oncol 1 3 (1999) 232-250
19. Pingoud-Meier C., Lang D., Janss A.J., Rorke L.B., Phillips P.C., Shalaby T., and Grotzer M.A. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 9 17 (2003) 6401-6409
20. Taipale J., Chen J.K., Cooper M.K., Wang B., Mann R.K., Milenkovic L., Scott M.P., and Beachy P.A. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406 6799 (2000) 1005-1009
21. MacDonald T.J., Brown K.M., LaFleur B., Peterson K., Lawlor C., Chen Y., Packer R.J., Cogen P., and Stephan D.A. Expression profiling of medulloblastoma. PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29 2 (2001) 143-152
22. Pomeroy S.L., Tamayo P., Gaasenbeek M., Sturla L.M., Angelo M., McLaughlin M.E., Kim J.Y., Goumnerova L.C., Black P.M., Lau C., Allen J.C., Zagzag D., Olson J.M., Curran T., Wetmore C., Biegel J.A., Poggio T., Mukherjee S., Rifkin R., Califano A., Stolovitzky G., Louis D.N., Mesirov J.P., Lander E.S., and Golub T.R. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415 6870 (2002) 436-442
23. Biegel J.A., Zhou J.Y., Rorke L.B., Stenstrom C., Wainwright L.M., and Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59 1 (1999) 74-79
24. Rezai A.R., Mogilner A.Y., Cappell J., Hund M., Llinas R.R., and Kelly P.J. Integration of functional brain mapping in image-guided neurosurgery. Acta Neurochir Suppl 68 (1997) 85-89
25. Duffner P.K., Horowitz M.E., Krischer J.P., Burger P.C., Cohen M.E., Sanford R.A., Friedman H.S., and Kun L.E. The treatment of malignant brain tumors in infants and very young children. an update of the Pediatric Oncology Group experience. Neuro-oncol 1 2 (1999) 152-161
26. Kun L. Principles of Radiation Therapy. 2 ed. (1994), Raven Press, New York 95-115
27. Swift P. Novel techniques in the delivery of radiation in pediatric oncology. Pediatr Clin North Am 49 5 (2002) 1107-1129
28. Hodgson D.C., Goumnerova L.C., Loeffler J.S., Dutton S., Black P.M., Alexander III E., Xu R., Kooy H., Silver B., and Tarbell N.J. Radiosurgery in the management of pediatric brain tumors. Int J Radiat Oncol Biol Phys 50 4 (2001) 929-935
29. Allen J., Siffert J., Donahue B., Nirenberg A., Jakacki R., Robertson P., DaRosso R., Thoron L., Rosovsky M., and Pinto R. A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer 86 6 (1999) 1064-1069
30. Ostryszja L. Gemcitabine and radiosensitization in two glioblasoma cell lines. Prec Amer Assoc Cancer Res 30 (1998) 382
31. Yamanaka R., Homma J., Yajima N., Tsuchiya N., Sano M., Kobayashi T., Yoshida S., Abe T., Narita M., Takahashi M., and Tanaka R. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma. results of a clinical phase I/II trial. Clin Cancer Res 11 11 (2005) 4160-4167
32. De Vleeschouwer S., Van Calenbergh F., Demaerel P., Flamen P., Rutkowski S., Kaempgen E., Wolff J.E., Plets C., Sciot R., and Van Gool S.W. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 100 5 Suppl Pediatrics (2004) 492-497
33. Lumniczky K., Desaknai S., Mangel L., Szende B., Hamada H., Hidvegi E.J., and Safrany G. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 9 1 (2002) 44-52
34. Boskovitz A., Wikstrand C.J., Kuan C.T., Zalutsky M.R., Reardon D.A., and Bigner D.D. Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther 4 9 (2004) 1453-1471
35. Martell L.A., Agrawal A., Ross D.A., and Muraszko K.M. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53 6 (1993) 1348-1353
36. Weaver M., and Laske D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65 1 (2003) 3-13
37. Taipale J., and Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 411 6835 (2001) 349-354
38. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 10 (2002) 727-739
39. Puduvalli V.K., and Sawaya R. Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors. J Neurooncol 50 1-2 (2000) 189-200
40. MacDonald T.J., Taga T., Shimada H., Tabrizi P., Zlokovic B.V., Cheresh D.A., and Laug W.E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48 1 (2001) 151-157
41. Parsa A. Gene Therapy in Tumor of the Pediatric Central nervous System. In: Keating R. (Ed). Tumor of the Pediatric Netral Nervous System (2001), Thieme, New York 184-195
42. Izquierdo M., Martin V., de Felipe P., Izquierdo J.M., Perez-Higueras A., Cortes M.L., Paz J.F., Isla A., and Blazquez M.G. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 3 6 (1996) 491-495
43. Packer R.J., Raffel C., Villablanca J.G., Tonn J.C., Burdach S.E., Burger K., LaFond D., McComb J.G., Cogen P.H., Vezina G., and Kapcala L.P. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 92 2 (2000) 249-254
44. Manome Y., Wen P.Y., Dong Y., Tanaka T., Mitchell B.S., Kufe D.W., and Fine H.A. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 2 5 (1996) 567-573
45. Cogen P.H., and McDonald J.D. Tumor suppressor genes and medulloblastoma. J Neurooncol 29 1 (1996) 103-112
46. Cheney I.W., Johnson D.E., Vaillancourt M.T., Avanzini J., Morimoto A., Demers G.W., Wills K.N., Shabram P.W., Bolen J.B., Tavtigian S.V., and Bookstein R. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 58 11 (1998) 2331-2334
47. Gondi C.S., Lakka S.S., Yanamandra N., Olivero W.C., Dinh D.H., Gujrati M., Tung C.H., Weissleder R., and Rao J.S. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 64 12 (2004) 4069-4077
48. Rorke L.B. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 42 1 (1983) 1-15
49. Duffner P.K., Cohen M.E., Myers M.H., and Heise H.W. Survival of children with brain tumors. SEER Program, 1973-1980. Neurology 36 5 (1986) 597-601
50. Dirks P.B., Harris L., Hoffman H.J., Humphreys R.P., Drake J.M., and Rutka J.T. Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 29 1 (1996) 75-84
51. Albright A.L., Wisoff J.H., Zeltzer P.M., Boyett J.M., Rorke L.B., and Stanley P. Effects of medulloblastoma resections on outcome in children. a report from the Children's Cancer Group. Neurosurgery 38 2 (1996) 265-271
52. Albright A.L., Wisoff J.H., Zeltzer P., Boyett J., Rorke L.B., Stanley P., Geyer J.R., and Milstein J.M. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children's Cancer Group. Pediatr Neurosurg 22 1 (1995) 1-7
53. Evans A.E., Jenkin R.D., Sposto R., Ortega J.A., Wilson C.B., Wara W., Ertel I.J., Kramer S., Chang C.H., Leikin S.L., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72 4 (1990) 572-582
54. Krischer J.P., Ragab A.H., Kun L., Kim T.H., Laurent J.P., Boyett J.M., Cornell C.J., Link M., Luthy A.R., and Camitta B. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 74 6 (1991) 905-909
55. Tait D.M., Thornton-Jones H., Bloom H.J., Lemerle J., and Morris-Jones P. Adjuvant chemotherapy for medulloblastoma. the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26 4 (1990) 464-469
56. Packer R.J., Sutton L.N., Elterman R., Lange B., Goldwein J., Nicholson H.S., Mulne L., Boyett J., D'Angio G., Wechsler-Jentzsch K., et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81 5 (1994) 690-698
57. Strother D., Ashley D., Kellie S.J., Patel A., Jones-Wallace D., Thompson S., Heideman R., Benaim E., Krance R., Bowman L., and Gajjar A. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy. results of a collaborative study. J Clin Oncol 19 10 (2001) 2696-2704
58. Reddy A.T., Janss A.J., Phillips P.C., Weiss H.L., and Packer R.J. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 88 9 (2000) 2189-2193
59. Thomas P.R., Deutsch M., Kepner J.L., Boyett J.M., Krischer J., Aronin P., Albright L., Allen J.C., Packer R.J., Linggood R., Mulhern R., Stehbens J.A., Langston J., Stanley P., Duffner P., Rorke L., Cherlow J., Friedman H.S., Finlay J.L., Vietti T.J., and Kun L.E. Low-stage medulloblastoma. final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18 16 (2000) 3004-3011
60. Jakacki R.I., Feldman H., Jamison C., Boaz J.C., Luerssen T.G., and Timmerman R. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int J Radiat Oncol Biol Phys 60 2 (2004) 531-536
61. Bailey C.C., Gnekow A., Wellek S., Jones M., Round C., Brown J., Phillips A., Neidhardt M.K., and International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. Med Pediatr Oncol 25 3 (1995) 166-178
62. Wara W.M., Le Q.T., Sneed P.K., Larson D.A., Prados M.D., Levin V.A., Edwards M.S., and Weil M.D. Pattern of recurrence of medulloblastoma after low-dose craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 30 3 (1994) 551-556
63. Packer R.J. 2340cGy of Craniospinal Radiotherapy (CSRT) plus Chemotherapy for Children with "Average-Risk" Medulloblastoma (MB). A Prospective Randomized Children's Oncology Group Study (A9961). Society for Neuroncology Meeting (2004)
64. Geyer J.R., Zeltzer P.M., Boyett J.M., Rorke L.B., Stanley P., Albright A.L., Wisoff J.H., Milstein J.M., Allen J.C., Finlay J.L., et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day. a report from the Childrens Cancer Group. J Clin Oncol 12 8 (1994) 1607-1615
65. Ater J.L., van Eys J., Woo S.Y., Moore III B., Copeland D.R., and Bruner J. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J Neurooncol 32 3 (1997) 243-252
66. White L., Johnston H., Jones R., Mameghan H., Nayanar V., McWhirter W., Kellie S., Waters K., and Toogood I. Postoperative chemotherapy without radiation in young children with malignant non-astrocytic brain tumours. A report from the Australia and New Zealand Childhood Cancer Study Group (ANZCCSG). Cancer Chemother Pharmacol 32 5 (1993) 403-406
67. Kuhl J.B., J, Bode U., Deinlein F., Gnekow A., Graf N., et al. Delayed radiation therapy (RT) after postoperative chemotherapy (PCH) in children less than 3 years of age with medulloblastoma. Results of the HIT-SKK'87 and preliminary results of the pilot trial HIT-SKK'92. Med Pediatr Oncol 25 (1995) 250
68. Grill J., Sainte-Rose C., Jouvet A., Gentet J.C., Lejars O., Frappaz D., Doz F., Rialland X., Pichon F., Bertozzi A.I., Chastagner P., Couanet D., Habrand J.L., Raquin M.A., Le Deley M.C., and Kalifa C. Treatment of medulloblastoma with postoperative chemotherapy alone. an SFOP prospective trial in young children. Lancet Oncol 6 8 (2005) 573-580
69. Dupuis-Girod S., Hartmann O., Benhamou E., Doz F., Mechinaud F., Bouffet E., Coze C., and Kalifa C. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?. J Neurooncol 27 1 (1996) 87-98
70. Guruangan S., Dunkel I.J., Goldman S., Garvin J.H., Rosenblum M., Boyett J.M., Gardner S., Merchant T.E., Gollamudi S., and Finlay J.L. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 16 7 (1998) 2486-2493
71. Merchant T.E., Happersett L., Finlay J.L., and Leibel S.A. Preliminary results of conformal radiation therapy for medulloblastoma. Neuro-oncol 1 3 (1999) 177-187
72. Wolden S.L., Dunkel I.J., Souweidane M.M., Happersett L., Khakoo Y., Schupak K., Lyden D., and Leibel S.A. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol 21 16 (2003) 3079-3083
73. Hallahan A.R., Pritchard J.I., Chandraratna R.A., Ellenbogen R.G., Geyer J.R., Overland R.P., Strand A.D., Tapscott S.J., and Olson J.M. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 9 8 (2003) 1033-1038
74. Hirsch J.F., Sainte Rose C., Pierre-Kahn A., Pfister A., and Hoppe-Hirsch E. Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg 70 4 (1989) 568-572
75. Albright A.L. Pediatric brain tumors. CA Cancer J Clin 43 5 (1993) 272-288
76. Kortmann R.D., Timmermann B., Taylor R.E., Scarzello G., Plasswilm L., Paulsen F., Jeremic B., Gnekow A.K., Dieckmann K., Kay S., and Bamberg M. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: Treatment modalities of radiation therapy. Strahlenther Onkol 179 8 (2003) 509-520
77. Rush J.A., Younge B.R., Campbell R.J., and MacCarty C.S. Optic glioma. Long-term follow-up of 85 histopathologically verified cases. Ophthalmology 89 11 (1982) 1213-1219
78. Alvord Jr. E.C., and Lofton S. Gliomas of the optic nerve or chiasm. Outcome by patients' age, tumor site, and treatment. J Neurosurg 68 1 (1988) 85-98
79. Deliganis A.V., Geyer J.R., and Berger M.S. Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery 38 6 (1996) 1114-1118 discussion 1118-1119
80. Pierce S.M., Barnes P.D., Loeffler J.S., McGinn C., and Tarbell N.J. Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and long-term effects. Cancer 65 1 (1990) 45-52
81. Radcliffe J., Packer R.J., Atkins T.E., Bunin G.R., Schut L., Goldwein J.W., and Sutton L.N. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 32 4 (1992) 551-554
82. Petronio J., Edwards M.S., Prados M., Freyberger S., Rabbitt J., Silver P., and Levin V.A. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg 74 5 (1991) 701-708
83. Packer R.J., Lange B., Ater J., Nicholson H.S., Allen J., Walker R., Prados M., Jakacki R., Reaman G., Needles M.N., et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11 5 (1993) 850-856
84. Mahoney Jr. D.H., Cohen M.E., Friedman H.S., Kepner J.L., Gemer L., Langston J.W., James H.E., Duffner P.K., and Kun L.E. Carboplatin is effective therapy for young children with progressive optic pathway tumors. a Pediatric Oncology Group phase II study. Neuro-oncol 2 4 (2000) 213-220
85. Packer R.J., Ater J., Allen J., Phillips P., Geyer R., Nicholson H.S., Jakacki R., Kurczynski E., Needle M., Finlay J., Reaman G., and Boyett J.M. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86 5 (1997) 747-754
86. Merchant T.E., Zhu Y., Thompson S.J., Sontag M.R., Heideman R.L., and Kun L.E. Preliminary results from a Phase II trail of conformal radiation therapy for pediatric patients with localised low-grade astrocytoma and ependymoma. Int J Radiat Oncol Biol Phys 52 2 (2002) 325-332
87. Saran F.H., Baumert B.G., Khoo V.S., Adams E.J., Garre M.L., Warrington A.P., and Brada M. Stereotactically guided conformal radiotherapy for progressive low-grade gliomas of childhood. Int J Radiat Oncol Biol Phys 53 1 (2002) 43-51
88. Packer R.J., Boyett J.M., Zimmerman R.A., Rorke L.B., Kaplan A.M., Albright A.L., Selch M.T., Finlay J.L., Hammond G.D., and Wara W.M. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial. Cancer 72 4 (1993) 1414-1421
89. Broniscer A., Iacono L., Chintagumpala M., Fouladi M., Wallace D., Bowers D.C., Stewart C., Krasin M.J., and Gajjar A. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children. results of a multiinstitutional study (SJHG-98). Cancer 103 1 (2005) 133-139
90. Sanghavi S.N., Needle M.N., Krailo M.D., Geyer J.R., Ater J., and Mehta M.P. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood. first report of the Children's Cancer Group-0952. Neuro-oncol 5 1 (2003) 8-13
91. Wisoff J.H., Boyett J.M., Berger M.S., Brant C., Li H., Yates A.J., McGuire-Cullen P., Turski P.A., Sutton L.N., Allen J.C., Packer R.J., and Finlay J.L. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 89 1 (1998) 52-59
92. Sposto R., Ertel I.J., Jenkin R.D., Boesel C.P., Venes J.L., Ortega J.A., Evans A.E., Wara W., and Hammond D. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 7 2 (1989) 165-177
93. Finlay J.L., Boyett J.M., Yates A.J., Wisoff J.H., Milstein J.M., Geyer J.R., Bertolone S.J., McGuire P., Cherlow J.M., Tefft M., et al., Childrens Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol 13 1 (1995) 112-123
94. Wolff J.E., Gnekow A.K., Kortmann R.D., Pietsch T., Urban C., Graf N., and Kuhl J. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 94 1 (2002) 264-271
95. Lashford L.S., Thiesse P., Jouvet A., Jaspan T., Couanet D., Griffiths P.D., Doz F., Ironside J., Robson K., Hobson R., Dugan M., Pearson A.D., Vassal G., and Frappaz D. Temozolomide in malignant gliomas of childhood. a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20 24 (2002) 4684-4691
96. Dolan M.E., and Pegg A.E. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3 6 (1997) 837-847
97. Warren K., Gervais A., Aikin A., Egorin M., and Balis F.M. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother Pharmacol 54 3 (2004) 206-212
98. Weber F., Asher A., Bucholz R., Berger M., Prados M., Chang S., Bruce J., Hall W., Rainov N.G., Westphal M., Warnick R.E., Rand R.W., Floeth F., Rommel F., Pan H., Hingorani V.N., and Puri R.K. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64 1-2 (2003) 125-137
99. Di Sapio A., Morra I., Pradotto L., Guido M., Schiffer D., and Mauro A. Molecular genetic changes in a series of neuroepithelial tumors of childhood. J Neurooncol 59 2 (2002) 117-122
100. Raffel C., Frederick L., O'Fallon J.R., Atherton-Skaff P., Perry A., Jenkins R.B., and James C.D. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 5 12 (1999) 4085-4090